Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes

Pathobiology

Volumn 80, Issue 1, 2012, Pages 32-40

  Cuadros, M ^a,c   Cano, C ^c   Lopez F J ^c   Lopez Castro R ^a   Concha, A ^a,b  

^a Department of Pathology ^*  (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Breast neoplasm; Gene expression profile; Human epidermal growth factor receptor 2 neu

Indexed keywords

CALD1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPLIN PROTEIN; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; KI 67 ANTIGEN; MESSENGER RNA; NEURAL WISKOTT ALDRICH SYNDROME PROTEIN; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN P53; RHO FACTOR; TPM4 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CELL MIGRATION; CHROMOSOME 17Q; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MIDDLE AGED; RECEPTOR, ERBB-2; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864098073     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000339431     Document Type: Article

References (44)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. (Pubitemid 17231334)
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712. (Pubitemid 19147683)
3. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726. (Pubitemid 34111379)
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, et al: Herceptin Adjuvant (HERA) Trial Study Team: trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672. (Pubitemid 41464705)
5. Cuadros M, Villegas R: Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol 2009;17:1-7.
6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, et al: Molecular portraits of human breast tumours. Nature 2000;406:747-752.
7. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, et al: Repeated observation of breast tumor subtypes in independent gene expression data set. Proc Natl Acad Sci USA 2003;100:8418-8423. (Pubitemid 36842560)
8. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874. (Pubitemid 32878711)
9. Naderi A, Ahmed AA, Wang Y, Brenton JD, Caldas C: Optimal amounts of fluorescent dye improve expression microarray results in tumor specimens. Mol Biotechnol 2005;30:151-154. (Pubitemid 41003437)
10. Karlsson E, Delle U, Danielsson A, Olsson B, Abel F, Karlsson P, Helou K: Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer. BMC Cancer 2008;8:254.
11. Van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536. (Pubitemid 34130608)
12. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al.: Gene-expression profiles to predict distant metastasis of lymphnodenegative primary breast cancer. Lancet 2005;365:671-679. (Pubitemid 40260888)
13. Mook S, Knauer M, Bueno-de-Mesquita JM, Retel VP, Wesseling J, Linn SC, Van't Veer LJ, Rutgers EJ: Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 2010;17:1406-1413.
14. ® in patients with breast cancer. Med Clin (Barc) 2011;136:627-632.
15. Bertucci F, Finetti P, Birnbaum D, Viens P: Gene expression profiling of inflammatory breast cancer. Cancer 2010;116(11 suppl):2783-2793.
16. Bertucci F, Borie N, Ginestier C, Groulet A, Charafe-Jauffret E, Adélaïde J, Geneix J, Bachelart L, Finetti P, Koki A, Hermitte F, Hassoun J, et al: Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene 2004;23:2564-2575. (Pubitemid 38520754)
17. Wilson KS, Roberts H, Leek R, Harris AL, Geradts J: Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am J Pathol 2002;161:1171-1185.
18. Sircoulomb F, Bekhouche I, Finetti P, Adélaïde J, Ben Hamida A, Bonansea J, Raynaud S, Innocenti C, Charafe-Jauffret E, Tarpin C, Ben Ayed F, Viens P, et al: Genome profiling of ERBB2-amplified breast cancers. BMC Cancer 2010;10:539.
19. Holbro T, Civenni G, Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110. (Pubitemid 36331969)
20. Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481. (Pubitemid 29220854)
21. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. (Pubitemid 350003059)
22. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43. (Pubitemid 46174133)
23. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27:1323-1333.
24. Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C, Bellet M, Fabregat X, Serrano S, Solé F: Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 2005;7:R267-R273.
25. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2006;31:e15.
26. Wu Z, Irizarry RA: Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J Comput Biol 2005;12:882-893. (Pubitemid 41170488)
27. Li C, Wong WH: Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001;98:31-36. (Pubitemid 32095858)
28. Guide to Probe Logarithmic Intensity Error (PLIER) Estimation. http://www.affymetrix.com/support/technical/technotes/plier-technote.pdf.
29. Kauffmann A, Gentleman R, Huber W: ArrayQualityMetrics - a bioconductor package for quality assessment of microarray data. Bioinformatics 2009;25:415-416.
30. Reimers M: Making informed choices about microarray data analysis. PLoS Comput Biol 2010;6:e1000786.
31. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-5121. (Pubitemid 32397092)
32. Vanden BI, Vanhentenrijk V, Drijkoningen M, Wlodarska I, Vandenberghe P, Wolf-Peeters C: Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology 2005;46:431-441. (Pubitemid 40516759)
33. Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, et al: Research article High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 2010;12:R25.
34. Dressman MA, Baras A, Malinowski R, Alvis LB, Kwon I, Walz TM, Polymeropoulos MH: Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res 2003;63:2194-2199. (Pubitemid 36538626)
35. Cuadros M, Talavera P, López FJ, Garcúa-Peréz I, Blanco A, Concha A: Real-Time RTPCR analysis for evaluating the Her2/neu status in breast cancer. Pathobiology 2010;77:38-45.
36. Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E, Hamilton-Dutoit S: Realtime quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. J Mol Diagn 2004;6:42-51. (Pubitemid 38208344)
37. Capizzi E, Gruppioni E, Grigioni AD, Gabusi E, Grassigli A, Grigioni WF, Fiorentino M: Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry. Diagn Mol Pathol 2008;17:220-226.
38. Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S: Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. Am J Clin Pathol 2008;129:563-570. (Pubitemid 352029275)
39. Staaf J, Ringner M, Vallon-Christersson J, Jonsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, et al: Identification of subtypes in HER2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 2010;28:1813-1820.
40. Abe K, Takeichi M: EPLIN mediates linkage of the cadherin catenin complex to F-actin and stabilizes the circumferential actin belt. Proc Natl Acad Sci USA 2008;105:13-19.
41. Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, Ye L, Mansel RE: Eplinalpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer 2008;16:7:71.
42. Bohil AB, Robertson BW, Cheney RE: Myosin-X is a molecular motor that functions in filopodia formation. Proc Natl Acad Sci USA 2006;103:12411-12416. (Pubitemid 44267273)
43. Boukhelifa M, Moza M, Johansson T, Rachlin A, Parast M, Huttelmaier S, Roy P, Jockusch BM, Carpen O, Karlsson R, Otey CA: The proline-rich protein palladin is a binding partner for profilin. FEBS J 2006;273:26-33.
44. Vlahovich N, Schevzov G, Nair-Shaliker V, Ilkovski B, Artap ST, Joya JE, Kee AJ, North KN, Gunning PW, Hardeman EC: Tropomyosin 4 defines novel filaments in skeletal muscle associated with muscle remodelling/regeneration in normal and diseased muscle. Cell Motil Cytoskeleton 2008;65:73-85.